Fiche publication
Date publication
novembre 2021
Journal
Current oncology (Toronto, Ont.)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AYAV Ahmet
Tous les auteurs :
Goislard de Monsabert C, Touchefeu Y, Guiu B, Campillo-Gimenez B, Farges O, Tougeron D, Baumgaertner I, Ayav A, Beuzit L, Pracht M, Lièvre A, Le Sourd S, Boudjema K, Rolland Y, Garin E, Boucher E, Edeline J
Lien Pubmed
Résumé
In the Yttrium-90 Microspheres in Cholangiocarcinoma (MISPHEC) single-arm phase 2 trial, concomitant chemotherapy and selective internal radiotherapy (SIRT) showed antitumor activity as a first-line treatment of unresectable intrahepatic cholangiocarcinomas (ICCs). In this sub-analysis, we aimed to evaluate one of the secondary endpoints, the health-related quality of life (QoL), evaluated with an EORTC QLQ-C30 instrument at the baseline and during treatment.
Mots clés
Yttrium-90, biliary tract cancer, chemotherapy, patient-reported outcomes, radioembolization
Référence
Curr Oncol. 2021 Nov 8;28(6):4530-4541
